Affimed N.V. (AFMD)

Trade AFMD now with
8/8/2018 7:35:18 AM Affimed Q2 Net Loss EUR 8.0 Mln Or EUR 0.13 Per Share
6/15/2018 5:17:42 AM Affimed Presents New Interim Data From Phase 1b Dose Escalation Study Evaluating AFM13
5/15/2018 7:49:11 AM Affimed Q1 Revenue €0.5 Mln Vs. €0.4 Mln Prior Year
5/3/2018 5:04:39 AM Affimed Announces Official Launch Of Its Redirected Optimized Cell Killing (ROCKTM) Platform
3/20/2018 7:38:49 AM Affimed Q4 Net Loss EUR 6.4 Mln Or EUR 0.14/Shr Vs Loss Of EUR 5.4 Mln Or EUR 0.19/Shr Last Year
3/19/2018 6:04:03 AM Affimed Appoints Leila Alland As Chief Medical Officer, Effective March 26
3/19/2018 6:03:56 AM Affimed Appoints Leila Alland To The Position Of Chief Medical Officer
3/15/2018 4:04:21 AM Affimed To Present Preclinical Data On AFM24 At AACR Annual Meeting 2018
2/13/2018 3:04:07 AM Affimed N.V. Announces Pricing Of Public Offering Of 11.5 Mln Shares At $2.00/shr
12/11/2017 5:04:08 AM Affimed Presents Data From Phase 1b Combination Study Of AFM13 With Pembrolizumab At ASH
11/7/2017 7:38:48 AM Affimed Q3 Net Loss EUR 8.1 Mln Or EUR 0.18 Per Share
11/1/2017 9:31:00 AM Affimed To Present Clinical And Preclinical Data On Immune Cell Engagers At ASH
8/1/2017 7:40:05 AM Affimed Posts Q2 Loss Per Share $0.18 Vs Loss $0.24 Last Year
6/27/2017 5:03:03 AM Affimed Reports Presentation Of Preclinical Data On AFM24 And AFM26 At EACR-AACR-SIC 2017
6/6/2017 5:02:04 AM Affimed Presents Data On First-in-Class BCMA-Targeting Immune Cell Engager AFM26 At ASCO Annual Meeting 2017
5/17/2017 7:33:13 AM Affimed N.V. Q1 Net Loss €7.8 Mln Or €0.19/shr Vs. Net Loss €8.5 Mln Or €0.25/shr Last Year
3/30/2017 7:33:58 AM Affimed Q4 Net Loss EUR 5.4 Mln Or EUR 0.16/shr Vs Loss Of EUR 6.3 Mln Or EUR 0.19/Shr Last Year